Apolipoprotein A-I concentrations and risk of coronary artery disease: A Mendelian randomization study
Year: 2020
Type: review
Study design: Observational Study
Abstract: Background and aims Apolipoprotein A-I (apoA-I) infusions represent a potential novel therapeutic approach for the prevention of coronary artery disease (CAD). Although circulating apoA-I concentrations inversely associate with risk of CAD, the evidence base of this representing a causal relationship is lacking. The aim was to assess the causal role of apoA-I using human genetics. Methods We identified a variant (rs12225230) in APOA1 locus that associated with circulating apoA-I concentrations ( p < 5 × 10 −8 ) in 20,370 Finnish participants, and meta-analyzed our data with a previous GWAS of apoA-I. We obtained genetic estimates of CAD from UK Biobank and CARDIoGRAMplusC4D (totaling 122,733 CAD cases) and conducted a two-sample Mendelian randomization analysis. We compared our genetic findings to observational associations of apoA-I with risk of CAD in 918 incident CAD cases among 11,535 individuals from population-based prospective cohorts. Results ApoA-I was associated with a lower risk of CAD in observational analyses (HR 0.81; 95%CI: 0.75, 0.88; per 1-SD higher apoA-I), with the association showing a dose-response relationship. Rs12225230 associated with apoA-I concentrations (per-C allele beta 0.076 SD; SE: 0.013; p = 1.5 × 10 −9 ) but not with confounders. In Mendelian randomization analyses, apoA-I was not related to risk of CAD (OR 1.13; 95%CI: 0.98,1.30 per 1-SD higher apoA-I), which was different from the observational association. Similar findings were observed using an independent ABCA1 variant in sensitivity analysis. Conclusions Genetic evidence fails to support a cardioprotective role for apoA-I. This is in line with the cumulative evidence showing that HDL-related phenotypes are unlikely to have a protective role in CAD.
Source: Atherosclerosis
Authors: Minna K. Karjalainen(Conceptualization, Formal analysis, Investigation, Methodology, Validation, Writing – original draft, Writing – review & editing), Michael V. Holmes(Conceptualization, Formal analysis, Funding acquisition, Investigation, Methodology, Project administration, Supervision, Validation, Writing – original draft, Writing – review & editing), Qin Wang(Conceptualization, Methodology, Writing – original draft, Writing – review & editing), Olga Anufrieva(Formal analysis, Investigation, Validation, Writing – review & editing), Mika Kähönen(Data curation, Resources, Writing – review & editing), Terho Lehtimäki(Data curation, Resources, Writing – review & editing), Aki S. Havulinna(Data curation, Resources, Writing – review & editing), Kati Kristiansson(Data curation, Resources, Writing – review & editing), Veikko Salomaa(Data curation, Resources, Writing – review & editing), Markus Perola(Data curation, Resources, Writing – review & editing), Jorma S. Viikari(Data curation, Resources, Writing – review & editing), Olli T. Raitakari(Data curation, Resources, Writing – review & editing), Marjo-Riitta Järvelin(Data curation, Resources, Writing – review & editing), Mika Ala-Korpela(Conceptualization, Data curation, Funding acquisition, Methodology, Project administration, Resources, Supervision, Writing – original draft, Writing – review & editing), Johannes Kettunen(Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Methodology, Project administration, Resources, Supervision, Validation, Writing – original draft, Writing – review & editing)
Institutions: University of Oulu, National Institute for Health and Care Research, University of Bristol, University of Oxford, NIHR Oxford Biomedical Research Centre, MRC Population Health Research Unit, MRC Integrative Epidemiology Unit, Baker Heart and Diabetes Institute, Tampere University, Tampere University Hospital, University of Tampere, Fimlab (Finland), Finnish Institute for Health and Welfare, Institute for Molecular Medicine Finland, HiLIFE – Elämäntieteiden Instituutti, University of Helsinki, University of Tartu, University of Turku, Turku University Hospital, Oulu University Hospital, MRC Centre for Environment and Health, Imperial College London, Brunel University of London, University of Eastern Finland, The Alfred Hospital, Monash University
Language: English
Subfield: Genetics
Domain: Life Sciences
Open Access status: hybrid
Estimated APC paid: $4,020
Funders: Yrjö Jahnssonin Säätiö, NIHR Bristol Biomedical Research Centre, National Institute for Health and Care Research, British Heart Foundation, European Commission, Kela, Academy of Finland, Suomen Kulttuurirahasto, Juho Vainion Säätiö, Novo Nordisk, Signe ja Ane Gyllenbergin Säätiö, State Government of Victoria, Emil Aaltosen Säätiö, Socialdepartementet, Sydäntutkimussäätiö, Oulun Yliopisto, Sigrid Juséliuksen Säätiö, Tampereen Tuberkuloosisäätiö, Diabetesliitto, Paavo Nurmen Säätiö, Novo Nordisk Fonden, Tays, Turun Yliopistollinen Keskussairaala, Terveyden ja hyvinvoinnin laitos, Horizon 2020 Framework Programme, Medical Research Council, European Research Council
Awards: G1037428335, G1084468243, G1362419404, G1386524577, G1572456532, G1872575776, G1892666461, G1979817184, G2172917756, G2294654675, G234837756, G247187792, G2513778610, G2664650210, G2727685138, A multidisciplinary approach for the stratification of patients with carotid artery disease, G3046112337, G3521192838, G3582688621, G3764564876, G5084050915, G5090981026, G5474452856, G5550897609, G5575437449, G5628355835, G5846620681, G6100258202, G6164432047, G6682689995, G696516675, G7540798381, G7743063307, G7827963676, G8475334665, G849339821, G8625427497, Drug target validation and risk prediction for coronary heart disease using targeted blood-based metabolomics and proteomics, G992154238
OpenAlex ID: W3006634014
